APTOCROM Acquires 50.8 Billion Won Convertible Bonds from Affiliate Aprogen Biologics for Financial Improvement

APTOCROM has decided to acquire 50.8 billion won of 20th series unregistered private convertible bonds issued by its affiliate Aprogen Biologics, through set-off of existing loan receivables.
The purpose is to improve financial structure. The conversion price is tentatively set at 3,778 won, to be finalized based on the stock price three trading days before the payment date. Conversion period is from July 6, 2027 to June 6, 2029.
The bonds include a put option starting January 6, 2028, 1.5 years after issuance.
The acquisition amount represents approximately 183% of APTOCROM's market capitalization, posing potential liquidity risk. Future conversion price adjustments and Aprogen Biologics' financial performance may affect investment recovery.
Aprogen Biologics reported total assets of 586.9 billion won, liabilities of 309.4 billion won, equity of 277.6 billion won, and a net loss of 168.3 billion won in 2025.
[AI Summary]This transaction is essentially a financial rearrangement between affiliates. While no direct dilution occurs for APTOCROM shareholders, a large asset is tied up in convertible bonds, creating liquidity risk. Given Aprogen Biologics' poor earnings and high debt, investment recovery is uncertain.